Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
Open Access
- 16 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 123 (5), 691-693
- https://doi.org/10.1038/s41416-020-0930-7
Abstract
The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation.Keywords
This publication has 21 references indexed in Scilit:
- Advances in cancer immunotherapy 2019 – latest trendsJournal of Experimental & Clinical Cancer Research, 2019
- Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Immunological Approaches Towards Cancer and Inflammation: A Cross TalkFrontiers in Immunology, 2018
- Immune checkpoint blockade in infectious diseasesNature Reviews Immunology, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Severe cytokine release syndrome in a patient receiving PD‐1‐directed therapyPediatric Blood & Cancer, 2017
- SARS and MERS: recent insights into emerging coronavirusesNature Reviews Microbiology, 2016
- The Acute Respiratory Distress Syndrome: From Mechanism to TranslationThe Journal of Immunology, 2015
- Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive InfectionThe Journal of Immunology, 2005
- Host Defense Response and Outcome in ARDSSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1997